|
|
Article: ALK-AbellA[superscript three], the Makers of GRAZAX(R), Present Successful Phase III Clinical Study Results with Children.(Clinical report)
- Article from:
- PR Newswire Europe
- Article date:
- March 17, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HORSHOLM, Denmark, March 17 /PRNewswire/ --
- Results Show Highly Significant Effect on Rhinoconjunctivitis (Hay Fever) and Asthma Symptoms in Children from age 5 to 16 Years-old
ALK-AbellA[sup.3] yesterday presented successful Phase III clinical study results with GRAZAX(R) in children at the American Academy of Allergy, Asthma & Immunology (AAAAI 2008) taking place in Philadelphia, Pennsylvania this week.
The main results from the GRAZAX(R) GT-12 study were presented to the scientific community. More than 250 patients participated in the randomized, double blind, placebo controlled trial.
In the grass pollen season (using a threshold ...